Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious and rare genetic skin diseases. Its lead product candidate is QTORIN rapamycin, a 3.9% anhydrous topical gel currently in Phase 3 clinical trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. The company also develops QTORIN rapamycin for angiokeratomas and other mTOR-driven skin diseases, as well as QTORIN pitavastatin for disseminated superficial actinic porokeratosis. Palvella is headquartered in Wayne, Pennsylvania, and operates in the United States.

Palvella Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol PVLA. The company's stock trades in U.S. dollars (USD), which is the official currency of the United States where the company is based. As a Nasdaq-listed company, Palvella is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission (SEC).

Palvella Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing therapies for rare genetic skin diseases, which falls under the broader biotechnology umbrella. Biotechnology companies like Palvella use biological processes and living organisms to develop drugs and treatments, often targeting conditions with limited existing therapies.

Palvella Therapeutics is headquartered in Wayne, Pennsylvania, United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its clinical trials and development activities are focused on addressing serious and rare genetic skin diseases, which are conditions that affect patients in the United States and potentially globally. However, based on available data, the company's operations and target market are centered in the U.S.